CAR-T To Go: Juno Sees JCAR017 As Safer, Suited For Outpatients

Data for JCAR017 in diffuse large B-cell lymphoma to be presented at the upcoming ASH meeting suggest that the therapy has best-in-class safety and efficacy, paving the way for use outside major medical centers, a potential competitive advantage.